Michael S Ip
Overview
Explore the profile of Michael S Ip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schildroth K, Peterson K, Altaweel M, Channa R, Chang J, Gottlieb J, et al.
Retina
. 2024 Oct;
44(11):1931-1936.
PMID: 39437216
Purpose: Historically, supplemental dextrose to infusion fluid has been used to reduce the need for intraoperative lensectomies to maintain visualization during diabetic vitrectomy. Valved, small-gauge vitrectomy has reduced surgical time...
2.
Schildroth K, Wingelaar M, Boeke P, Ip M, Chang J, Gottlieb J, et al.
Eye (Lond)
. 2024 May;
38(14):2731-2736.
PMID: 38745084
Background: Silicone oil (SO) is a long-term tamponade for repair of complex retinal pathology but has limitations including late redetachment. This study describes our experience with SO tamponade for repair...
3.
Scott I, Oden N, Ip M, VanVeldhuisen P, Blodi B
Am J Ophthalmol
. 2024 May;
266:110-117.
PMID: 38705553
Purpose: To investigate the association of retinal thickness 1 month after the first study aflibercept or bevacizumab injection with later retinal thickness, visual acuity, and number of treatments in eyes...
4.
Scott I, Oden N, VanVeldhuisen P, Ip M, Blodi B
Ophthalmology
. 2024 Apr;
131(6):e25-e26.
PMID: 38573249
No abstract available.
5.
Zarbin M, MacCumber M, Karcher H, Adiguzel E, Mayhook A, LaPrise A, et al.
Ophthalmol Ther
. 2024 Mar;
13(5):1357-1368.
PMID: 38520643
Introduction: To assess real-world safety outcomes for adults with neovascular age-related macular degeneration (nAMD) treated with brolucizumab from the US-based IRIS® (Intelligent Research in Sight) Registry. Methods: In this retrospective...
6.
Regillo C, Nijm L, Shechtman D, Kaiser P, Karpecki P, Ryan E, et al.
Clin Ophthalmol
. 2024 Feb;
18:325-335.
PMID: 38332904
Newly approved treatments for patients with geographic atrophy are changing the treatment paradigm, highlighting the need for eye care providers (ECPs) to have a set of recommendations on how to...
7.
Ip M, Scott I, VanVeldhuisen P, Oden N, Blodi B
Am J Ophthalmol
. 2023 Dec;
260:147-159.
PMID: 38061584
Purpose: To evaluate imaging findings from SCORE2 participants through 60 months, to describe the degree of resolution or progression of these variables, and to correlate changes in these imaging findings...
8.
Singh R, Barakat M, Ip M, Wykoff C, Eichenbaum D, Joshi S, et al.
JAMA Ophthalmol
. 2023 Nov;
141(12):1152-1160.
PMID: 37971723
Importance: Despite the effectiveness of existing anti-vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and/or reduce injection or monitoring frequency in...
9.
Aref A, Scott I, Oden N, Ip M, VanVeldhuisen P, Blodi B
JAMA Ophthalmol
. 2023 Nov;
141(12):1172-1174.
PMID: 37943541
No abstract available.
10.
Kaiser P, Karpecki P, Regillo C, Baumal C, Ryan E, Ip M, et al.
BMJ Open Ophthalmol
. 2023 Oct;
8(1).
PMID: 37857560
Background/aims: With a paradigm shift in geographic atrophy (GA) treatments now available, establishing consensus on the identification and diagnosis of the disease along with considerations for management of patients with...